- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03299881
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study employs a randomized, adaptive, parallel arm study in which, cohorts of enrolled subjects (25 per arm) are assessed for dose response and progression to achievement of primary and secondary endpoints. Enrollment will be up to 300 subjects at 4 US centers.
After signing informed consent, subjects will be screened during a one week screening/baseline period to determine if they meet the inclusion criteria and exhibit none of the exclusion criteria. Weight, blood pressure, blood lipids, HgA1c, pregnancy test (for women of childbearing age), and patient questionnaires will be collected. If eligible, subjects will be randomized to treatment or control groups. The treatment group will receive training on the Elira Wearable Patch System and the first TENS session will be administered in the investigators office. Both groups will receive an electronic scale and instructions on 1200 calorie diet as well as diary completion requirements to be completed throughout the study. All subjects will be required to have in office follow-up visits every 4 weeks for 12 weeks. Up to 2 additional follow-up visits will be permitted within that 12 week time period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63017
- St. Louis Women's Healthcare Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is between 18 - 65 years of age inclusive.
- Subject has a BMI of 25-35 kg/ m^2 inclusive.
- Subject has signed the informed consent form and is able to comply with study protocol and adhere to study visit schedule.
- Subject is able to wear and use a wearable, patch TENS system.
- Subject is able to use a touch screen hand held smart phone.
- Subject is fluent in English and can complete patient questionnaires.
- Subject can comply with a 1200 calorie the recommended diet for the duration of the study.
- Subject is male or non-pregnant, non-lactating female, who agrees to use effective contraceptive methods throughout the length of the trial based on PI approval.
- Females of childbearing potential must have a negative urine pregnancy test at enrollment visit, prior to placement of ELIRA device.
Exclusion Criteria
- Subject has any known gastrointestinal disorder that in the opinion of the PI precludes enrollment into the trial.
- Subject has had a prior bariatric procedure.
- Subject has any significant multisystem disease in the opinion of the PI.
- Subject has > 6.5 HbA1c.
- Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular disease.
- Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
- Subject is a female of child-bearing potential who is pregnant or intends to become pregnant during the trial.
- Subject has a history of any malignancy in the last 2 years.
- Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months prior to enrollment.
- Subject has a moderate / severe psychiatric disorder.
- Subject has a diagnosed neurological disease.
- Subject has a diagnosed eating disorder.
- Subject has a skin disorder affecting the thoracic dermatomes.
- Subject has abdominal surgery or other scars which may interfere with stimulation in the opinion of the PI.
- Subject is currently enrolled in other, potentially confounding research.
- Subject has known allergic reaction to materials in the electrodes and/or is otherwise unable to tolerate stimulation with the wearable TENS system.
- Subject is actively participating or unwilling to discontinue participation in another weight loss program.
- Subject is taking weight loss control medications including but not limited to OTC medications, Metformin, and Belviq.
- Subject is unable to take anti-nausea medications planned for the study.
- Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).
- Current smoker or user of nicotine product or smoking cessation within 1 year of the screening date.
- History of treatment for or current abuse of drugs or alcohol.
- A score of ≥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate depression.
- Any subject that the investigator considers inappropriate for the study for medical reasons.
- Subject has a history of migraine and/or is taking Topiramate for severe headache disorders.
- Subject is on hormonal or other drug therapy which may alter antral motility or appetite, per physician discretion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals.
Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
|
Subjects to be instructed on a healthy 1200 calorie diet.
The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
|
Active Comparator: Control
Open label diet and exercise counseling only.
Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
|
Subjects to be instructed on a healthy 1200 calorie diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Events
Time Frame: 12 weeks
|
Safety/Tolerability will be assessed by the non-inferiority of incidence of serious adverse events (SAEs), unanticipated DAEs (USAEs), device-related SAEs (DSAEs), and unanticipated device-related SAEs (UDAEs) that are associated with the TENS therapy throughout the stimulation and the follow-up period versus historical control (compared with other TENS systems).
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shelby Sullivan, MD, Consultant
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Diet & Exercise
-
USDA Grand Forks Human Nutrition Research CenterWithdrawn
-
Universidade Católica PortuguesaAssociação para o Desenvolvimento do Centro Académico de Investigação e Formação...Active, not recruitingCardiovascular Disease RiskPortugal
-
Göteborg UniversityThe Swedish Research Council; Swedish Council for Working Life and Social ResearchCompleted
-
Florida International UniversityTerminatedDiabetes | Frailty | Senior SyndromeUnited States
-
Rabin Medical CenterSoroka University Medical Center; D-Cure, IsraelCompleted
-
University of PittsburghUniversity of PennsylvaniaCompleted
-
Changi General HospitalCompletedQuality of Life | Inflammation | Sexual Dysfunction | Endothelial DysfunctionSingapore
-
Grupo de Investigación en Actividad Física y SaludCompletedCancer SurvivorsSpain
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileTerminatedMetabolic SyndromeChile
-
Rio de Janeiro State UniversityCompleted